HPV Testing: A Global Strategic Business Report
San Jose, California (PRWEB) April 22, 2015
Follow us on LinkedIn – Cervical cancer is the second most prevalent form of cancer affecting women. Smoking, early age coitarche, multiple sexual partners, and irregular screening are some of the high-risk factors for cervical cancer. However, in most instances, the disease is attributed to infection of genitals with human papilloma virus (HPV). HPV generally causes infection in mouth, genitals, hands, and fingers. Increasing awareness about the link between cervical cancer incidence and HPV, globally, is driving the focus on HPV testing. The market also stands to benefit from the development of advanced tests offering better detection capabilities.
While pap smear testing has long been the widely used primary screening test for cervical cancer diagnosis, lower test sensitivity, high level of false-negative results, and inadequate follow up after positive test results are shifting the focus onto HPV testing. Greater sensitivity and improved protection against cervical cancer and high-grade cervical lesions compared to cytology-based tests has led to HPV tests being used as a primary cervical cancer screening test in several countries. The April 2014 approval of Roche’s cobas HPV Test by the US FDA for use as a first-line primary screening tool for cervical cancer diagnosis in women aged 25 years and older exemplifies the potential of HPV tests for primary screening purposes.
In the coming years, the global HPV testing market is expected to make rapid gains, driven by the rising incidence of cervical cancer across the world and the growing emphasis on early detection and prevention. Increasing use of HPV tests as a primary screening tool for cervical cancer in women older than 25 years, growing use of Pap/HPV co-testing for women aged 30 years and older, and treatment guidelines in favor of HPV tests for screening even HPV vaccinated women are other factors fuelling market growth. While vaccines have been approved for screening in women up to 26 years, the vaccines offer protection only against the highest risk HPV types. The fact that HPV vaccination does not preclude female population from cervical cancer screening will continue to drive sales of HPV tests even among vaccinated women.
As stated by the new market research report on HPV Testing, the United States represents the largest market worldwide. While penetration rates below 50% and recommendations favoring longer co-testing intervals exert downward pressure on growth, rising incidence of cervical cancer, and positive government efforts in organizing awareness, screening, diagnosis and immunization programs, will spur growth. Also, the US FDA’s approval of Roche’s cobas HPV test for primary screening will contribute to growth in the market. Developing markets across Asia-Pacific and Latin America are expected to grow at a relatively faster rate than the United States as over 80% of the new cases are reported annually in these markets. The greater convenience associated with HPV testing compared to Pap smear tests will help spur adoption in under-penetrated emerging markets.
Major players covered in the report include Abbott Molecular Inc., Arbor Vita Corporation, Becton, Dickinson and Company, DaAn Gene Co. Ltd., F. Hoffmann-La Roche Ltd., Hologic Inc., QIAGEN N., and Seegene Inc.
The research report titled “HPV Testing: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive review of market trends, issues, drivers, mergers, acquisitions and other strategic industry activities of major players worldwide. The report provides market estimates and projections in US$ Thousand for all major geographic markets such as the US, Japan, Europe (France, Germany, Italy, UK, and Rest of Europe), and Rest of World.
For more details about this comprehensive market research report, please click here
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes 1500+ full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.
Global Industry Analysts, Inc.
Web Site: http://www.StrategyR.com/